PLAY PODCASTS
S2 Ep7: Kami Maddocks, MD, on Rituximab Rechallenging and Second-Line Therapies for R/R DLBCL
Season 2 · Episode 7

S2 Ep7: Kami Maddocks, MD, on Rituximab Rechallenging and Second-Line Therapies for R/R DLBCL

Oncology On The Go

July 30, 202114m 25s

Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Original episode page

Show Notes

CancerNetwork spoke with Kami Maddocks MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University, about CD-19 directed agents, avoiding rechallenging with rituximab, and second-line outcomes for transplant-ineligible patients with diffuse large B-cell lymphoma (DLBCL).
 
Visit cancernetwork.com to check out the first episode of this 3-part series here.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
← All episodes of Oncology On The Go